论文部分内容阅读
目的观察心阳片对急性失代偿性心力衰竭住院患者的短期治疗效果。方法采用随机、对照的临床研究方法,选取86例急性失代偿性心力衰竭的住院患者,按1∶1分为心阳片治疗组及对照组,两组患者均接受标准的西医基础治疗,治疗组在基础治疗上加用心阳片口服,4片/次,3次/日。观察住院期间患者病死率、心衰恶化率、住院天数、心衰反复频数、血管活性药物静脉使用时间(VDUT)等指标,同时检测入院及出院时血浆脑钠肽(BNP)、超敏C反应蛋白(Hs-CRP)水平及心功能。结果治疗组住院天数、心衰反复频数、VDUT均少于对照组(均P<0.05);两组患者出院前血浆BNP、Hs-CRP浓度较入院时均显著下降(均P<0.01),治疗组下降较对照组更明显(均P<0.05);治疗组心功能分级改善优于对照组(P<0.05),两组治疗后左室射血分数(LVEF)均较治疗前改善(均P<0.01),左室舒张末内径(LVEDD)均显著缩小(均P<0.05),治疗组LVEF改善较对照组更明显(P<0.05),组间LVEDD比较无显著差异(P>0.05);两组患者住院期间病死率、心衰恶化率比较无显著性差异(均P>0.05)。结论对于急性失代偿性心力衰竭住院患者,在西医常规治疗基础上加用心阳片治疗能缩短住院天数及血管活性药物使用时间,减少心衰反复,且能改善心功能,可能对其预后有积极影响。
Objective To observe the effect of Xinyang Tablet on short-term treatment of hospitalized patients with acute decompensated heart failure. Methods A randomized, controlled clinical study was conducted to select 86 hospitalized patients with acute decompensated heart failure. The patients were divided into Xinyang tablet treatment group and control group according to 1: 1. Both groups received standard western medicine treatment, Treatment group in the basic treatment plus Xinyang tablets oral, 4 tablets / time, 3 times / day. The mortality, worsening rate of heart failure, days of hospitalization, recurrence frequency of heart failure and VDUT were observed during hospitalization. At the same time, plasma BNP and Hypersensitivity C responses Protein (Hs-CRP) levels and cardiac function. Results The hospitalization days, heart failure frequency and VDUT in the treatment group were less than those in the control group (all P <0.05). The plasma BNP and Hs-CRP concentrations in both groups were significantly lower than those at admission (all P <0.01) (P <0.05). The improvement of cardiac function in the treatment group was better than that in the control group (P <0.05). The left ventricular ejection fraction (LVEF) in both groups was significantly improved after treatment (P (P <0.05). There was no significant difference in the LVEDD between the two groups (P> 0.05). The LVEDD decreased significantly (all P <0.05) There was no significant difference between the two groups in hospital mortality and heart failure (all P> 0.05). Conclusion In patients hospitalized with acute decompensated heart failure, XENYANG tablets can reduce the length of hospital stay and vasoactive drug use, reduce the recurrence of heart failure and improve cardiac function, which may have a prognosis of positive influence.